Recent Press Releases

Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application

BERKELEY, CA--(Marketwire - Feb 25, 2013) - Dynavax Technologies Corporation ( NASDAQ : DVAX ) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug...

NIH-funded researchers begin trial of Shigella vaccine candidates

Aim to thwart a principal cause of diarrheal disease worldwide Researchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella,...

Boys Get Their World-First Dose of Gardasil® to Protect Against HPV

Australian schoolboys have begun receiving the first of three vaccinations to protect them against cancers and disease caused by the human papillomavirus (HPV), Health Minister Tanya Plibersek has...

FluGen's Universal Flu Vaccine REDEE FLU™ Showcased at World Health Organization Influenza Meeting

MADISON, Wis.— Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU™. At the World Health Organization...

Study suggests link between untreated depression and response to shingles vaccine

Researchers measured immune response to vaccination among older adults [EMBARGOED FOR FEB. 14, 2013] Results from a new study published in Clinical Infectious Diseases suggest a link between...

PharmaJet's Stratis® Needle-free Injector Receives WHO PQS Certification as a Pre-qualified Delivery Device for Vaccine Administration

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World...

Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe

Vienna (Austria), February 12, 2013 – Intercell AG (VSE; "ICLL") announced today that the pediatric indication for IXIARO®, a vaccine to protect against Japanese Encephalitis (JE), was...

Major Commitment Achieved for Development of Vaccines Against Pregnancy-Associated Malaria

EUR16 million raised with support from European Vaccine Initiative to advance development of vaccines against placental malaria, a major cause of infant and maternal death HEIDELBERG,...

Has the 'Golden Age' of Global Health Funding Come to an End?

Feb. 6, 2013 — Despite dire predictions in the wake of the economic crisis, donations to health projects in developing countries appear to be holding steady, according to new research from the...

VAXIMM reports positive topline data from first oral cancer vaccine trial

- Study meets endpoints and demonstrates safety and tolerability of VXM01 -...

BUSM Study Highlights Attitudes Toward HPV Vaccination for Boys

January 30th, 2013 A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents/guardians were receptive toward vaccinating boys against Human Papilloma...

Injection-free vaccination technique could address global vaccine challenge for diseases such as HIV and malaria

Scientists at King's College London have demonstrated the ability to deliver a dried live vaccine to the skin without a traditional needle, and shown for the first time that this technique is...

Medicago and Investissement Québec Agree to a Three Year Extension of its $15.3M Loan

QUEBEC CITY, Feb. 5, 2013- Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing...

GAVI funds vaccines to protect girls against cervical cancer

Support for HPV vaccine pilot programmes approved for eight developing countries Geneva, 4 February 2013 – More than 180,000 girls in eight developing countries are set to receive protection...

Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis

Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis Merck Serono granted option for...

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

Data were published in The Lancet today from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate...

Nanoparticle Tracking Analysis for vaccine characterization at Lomonosov Moscow State University

The MSU Department of Virology headed by Professor Joseph Atabekov is studying the in vitro assembly of compositions, consisting of artificial plant virus particles and antigens, potentially...

Immunovaccine Signs Agreement for Phase I/II Clinical Trial of DPX-0907 in Breast and Ovarian Cancer Patients

First Clinical Trial in Europe with DepoVax-based Cancer Vaccine Halifax, Nova Scotia; January 30, 2013 – Immunovaccine Inc. (TSX-V: IMV), a clinical stage vaccine company, today announced the...

Life Technologies Establishes International Influenza Network

-- Scientists at leading public health agencies and research institutes collaborate to develop faster, more reliable flu subtyping methods -- Partners sharing data on Life's Ion Torrent...

Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease

Prevnar 13 is the First and Only Pneumococcal Conjugate Vaccine Approved for This Age Group NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug...